Ascendis Pharma A/S (Nasdaq: ASND) has recently revealed an exclusive license agreement with Teijin Limited to advance the development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP, specifically targeting endocrinology rare diseases in Japan.
Jan Mikkelsen, Ascendis Pharma's President and CEO, expressed satisfaction with the partnership, highlighting Teijin Pharma's expertise in obtaining regulatory approval and commercializing rare disease and endocrinology product candidates in Japan. Mikkelsen emphasized that the collaboration signifies a significant stride towards achieving a global presence for Ascendis Pharma's current Endocrinology Rare Disease portfolio, aiming to address unmet medical needs among Japanese patients.
Ascendis Pharma's innovative TransCon technology platform, praising the suite of product candidates as highly differentiated with best-in-class potential. Uchikawa anticipated that the partnership would greatly contribute to advancing Teijin Limited's healthcare business vision, especially in addressing issues faced by patients, families, and communities dealing with rare and intractable diseases.
According to the agreement's terms, Ascendis Pharma is set to receive an upfront payment of $70 million, coupled with potential development and regulatory milestones totaling up to $175 million, transfer pricing, and additional commercial milestones. Furthermore, Ascendis Pharma stands to gain royalties on net sales in Japan, ranging up to the mid-20s percent, with variations based on the specific product.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!